Marlene Fritsche

Marlene Fritsche

Auto-generated profile, based on publicly available information

Marlene Fritsche

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm 171 77, Sweden

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2025 in Science Signaling
Verified
Journal Article
Closed access
MFMarlene Fritsche
Marlene Fritsche
GPGaia Picozzi
Gaia Picozzi
TNTomas Nyman
Tomas Nyman
HZHugo Zeberg
Hugo Zeberg
RÅRichard Ågren
Richard Ågren
G protein–coupled receptors (GPCRs) play key roles in neurodevelopment by regulating excitatory and inhibitory neuronal pathways. The G protein subunit Gα i1 is a downstream effector of inhibitory GPCR signaling, and the gene encoding it ( GNAI1 ) is abundantly expressed in the brain. Rare GNAI1 variants are linked to a severe neurodevelopmental disorder called GNAI1 syndrome, which is characterized by intellectual disability, a range of movement issues, and epilepsy. Here, we investigated the effect of five GNAI1 syndrome–associated missense variants on GPCR signaling. Predictions based on genetic biobank data and in silico modeling suggested that these variants were pathogenic. Compared with the wild-type protein, four Gα i1 variants (T48K, T48I, C224Y, and V332E) showed marked increases in dopamine potency at the dopamine D2 receptor (D2R) and increased constitutive G protein activity when expressed in Xenopus laevis oocytes. By contrast, the Gα i1 G40C variant was unresponsive to D2R activation. All Gα i1 variants displayed reduced GTP-γ-S binding rates and undetectable GTP hydrolysis, except for the T48I variant, which showed more rapid binding and hydrolysis. Thus, four GNAI1 syndrome variants caused a net gain-of-function effect on D2R signaling, and all studied variants disrupted GTP exchange. These biochemical effects may underlie GNAI1 syndrome, and GNAI1 mutations should therefore be considered when screening for rare neurodevelopmental disorders.